Home › Oligodendroglioma › Pennsylvania
Oligodendroglioma clinical trials in Pennsylvania
3 studies for Oligodendroglioma are looking for participants at sites in Pennsylvania.
Cities in Pennsylvania
Study of Olutasidenib and Temozolomide in HGG
- Children's Hospital of Philadelphia, Philadelphia
RecruitingPhase 2
Ages 12 to 39 · All sexes · Updated Sep 1, 2026 · NCT06161974SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Thomas Jefferson University Hospital, Philadelphia
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT05303519All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
- University of Pennsylvania, Philadelphia
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Feb 20, 2026 · NCT05345002From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.